MX369060B - Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados. - Google Patents

Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados.

Info

Publication number
MX369060B
MX369060B MX2017003060A MX2017003060A MX369060B MX 369060 B MX369060 B MX 369060B MX 2017003060 A MX2017003060 A MX 2017003060A MX 2017003060 A MX2017003060 A MX 2017003060A MX 369060 B MX369060 B MX 369060B
Authority
MX
Mexico
Prior art keywords
melanin
disorders
conditions
ocular diseases
precursors
Prior art date
Application number
MX2017003060A
Other languages
English (en)
Other versions
MX2017003060A (es
Inventor
Solis Herrera Arturo
Original Assignee
Solis Herrera Arturo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solis Herrera Arturo filed Critical Solis Herrera Arturo
Publication of MX2017003060A publication Critical patent/MX2017003060A/es
Publication of MX369060B publication Critical patent/MX369060B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen usos de melanina y sus derivados, análogos y precursores para el tratamiento y prevención de enfermedades, trastornos y condiciones oculares; melanina, o un derivado, análogo o precursor de la misma, tal como melanina sintética o melanina natural, es aplicada al ojo mediante aplicación tópica o inyección; ejemplos de enfermedades, trastornos y condiciones oculares que pueden ser tratadas o prevenidas o mediante los métodos aquí descritos incluyen hiperemia, leucoplasia, angiogénesis de córnea, y queratocono de córnea.
MX2017003060A 2014-09-09 2015-09-08 Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados. MX369060B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048013P 2014-09-09 2014-09-09
PCT/IB2015/001570 WO2016038441A1 (en) 2014-09-09 2015-09-08 Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives

Publications (2)

Publication Number Publication Date
MX2017003060A MX2017003060A (es) 2017-11-17
MX369060B true MX369060B (es) 2019-10-28

Family

ID=55458388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003060A MX369060B (es) 2014-09-09 2015-09-08 Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados.

Country Status (10)

Country Link
US (1) US10220021B2 (es)
EP (1) EP3190887B1 (es)
JP (1) JP6499290B2 (es)
KR (3) KR102256185B1 (es)
CN (1) CN107072203B (es)
CA (1) CA2960583C (es)
ES (1) ES2855076T3 (es)
MX (1) MX369060B (es)
RU (1) RU2672564C2 (es)
WO (1) WO2016038441A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6716130B2 (ja) * 2016-07-04 2020-07-01 学校法人中部大学 抗アレルギー剤
WO2021225657A2 (en) * 2020-02-06 2021-11-11 Avisa Myko, Inc. Protection from ionizing radiation
CN111419793A (zh) * 2020-04-29 2020-07-17 上海紫河生物科技有限公司 一种含富勒烯及其衍生物的滴眼液及其制备方法
WO2023151788A1 (en) * 2022-02-09 2023-08-17 Katairo Gmbh Melanin for treating lipofuscin-associated diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
EP1119252A4 (en) 1998-08-21 2004-03-03 Childrens Medical Center USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION
US20030096735A1 (en) * 2001-09-28 2003-05-22 D'amato Robert J. Use of melanin for inhibition of angiogenesis and macular degeneration
WO2000040262A1 (en) 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
WO2003060131A1 (fr) * 2002-01-09 2003-07-24 Suntory Limited Transferase gn-t de sucre presentant un effet angiogenique
DK1900850T3 (da) 2005-06-09 2014-11-10 Herrera Arturo Solis Fotoelektrokemisk metode til separering af vand i brint og ilt under brug af melanier som det centrale elektrolyseelement
EA016227B1 (ru) * 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
WO2007102724A2 (es) * 2006-03-08 2007-09-13 Solis Herrera Arturo Efectos de la propiedad fotoelectrolizante de las melaninas, sus análogos y sus derivados, sobre la biología celular y su utilización con fines diversos
EP2801360B1 (en) 2006-05-08 2018-04-25 Arturo Solis Herrera The use of nicotine for the treatment of post traumatic bleeding in humans
US20100010082A1 (en) 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
KR101271593B1 (ko) * 2010-07-16 2013-06-11 대우제약 주식회사 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물

Also Published As

Publication number Publication date
JP6499290B2 (ja) 2019-04-10
RU2017111579A3 (es) 2018-10-10
CN107072203A (zh) 2017-08-18
RU2672564C2 (ru) 2018-11-16
KR20190005218A (ko) 2019-01-15
KR102299096B1 (ko) 2021-09-07
EP3190887A4 (en) 2018-04-25
CA2960583A1 (en) 2016-03-17
KR102256185B1 (ko) 2021-05-26
RU2017111579A (ru) 2018-10-10
EP3190887A1 (en) 2017-07-19
JP2017527622A (ja) 2017-09-21
EP3190887B1 (en) 2020-12-09
ES2855076T3 (es) 2021-09-23
KR20200015857A (ko) 2020-02-12
US20170296511A1 (en) 2017-10-19
US10220021B2 (en) 2019-03-05
CA2960583C (en) 2019-01-15
MX2017003060A (es) 2017-11-17
WO2016038441A1 (en) 2016-03-17
CN107072203B (zh) 2020-07-03
KR20170043655A (ko) 2017-04-21

Similar Documents

Publication Publication Date Title
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2017003060A (es) Metodos para tratar y prevenir enfermedades, trastornos y condiciones oculares con melanina y analogos de melanina, precursores y derivados.
PH12018501066A1 (en) Plant growth regulator composition having synergistic effect
EA201790958A1 (ru) Сублингвальный препарат рилузола
PH12017500747B1 (en) Heterocyclic compound
EP3405159A4 (en) TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
EA201690936A1 (ru) Применение цистеамина и его производных для лечения митохондриальных заболеваний
IL269127A (en) Derivatives of desmetylantol triton for the treatment of diseases related to the generation of reactive oxygen species (ROS) of mitochondrial origin
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PL3407879T3 (pl) Gabapentyna okulistyczna do leczenia wrzodów rogówki
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
IL269133A (en) Eye drops for the treatment of irritation without infection
MX2020007183A (es) Inhibidores de ret9 y vegfr2.
EA201691460A1 (ru) Композиция для ослабления боли, стресса и нарушения сна
UA108139U (uk) Спосіб терапії корів з ендометритом, як профілактика гонадопатій
MX2015017129A (es) Uso de acetato de leuprolida como neurorregenerador.
GB2544385A (en) Modulators of caspase-6

Legal Events

Date Code Title Description
FG Grant or registration